FDA fast-tracks Alexion's Ultomiris in 2nd Soliris indication

FDA fast-tracks Alexion's Ultomiris in 2nd Soliris indication

Source: 
Fierce Pharma
snippet: 

Alexion’s successor drug Ultomiris has snagged a priority review from the FDA to treat atypical hemolytic uremic syndrome (aHUS), an ultra-rare disease that can cause progressive damage to vital organs, the drugmaker said Thursday. The FDA’s approval decision date is Oct. 19.